Circulating biomarkers to guide systemic therapy for urothelial carcinoma.

doi:10.1016/j.urolonc.2016.08.019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Circulating biomarkers to guide systemic therapy for urothelial carcinoma.

Urologic oncology - 1 Nov 2016

Abbosh Philip H, Rosenberg Jonathan E, Plimack Elizabeth R

Abstract excerpt

There are very few biomarkers used to diagnose bladder cancer and no clinically approved biomarkers for prediction or prognostication of this disease. All currently available biomarkers are based on urine tests, and thus, they may not be applicable to patients with extravesical tumors. Biopsy of metastatic sites requires an invasive procedure, whereas serum-based markers, which can be easily obtained and serially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Cell Separation
Share to Drug Monitoring
Share to Forecasting

Source

Open in PubMed

Identifiers

PMID: 27751785
DOI: 10.1016/j.urolonc.2016.08.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Invasiveness

Share to Neoplastic Cells, Circulating

Share to RNA, Neoplasm

Share to Urologic Neoplasms